Skip to main content
$30.35 -$1.00 (-3.2%)

04:00 PM EDT on 07/23/21

Pacific Biosciences of California, Inc. (NASDAQ:PACB)

CAPS Rating: 3 out of 5

Current Price $30.35 Mkt Cap $6.0B
Open $31.35 P/E Ratio 0.00
Prev. Close $30.35 Div. (Yield) $0.00 (0.0%)
Daily Range $29.83 - $31.41 Volume 3,010
52-Wk Range $3.57 - $53.69 Avg. Daily Vol. 2,081,512

Caps

How do you think NASDAQ:PACB will perform against the market?

Add Stock to CAPS Watchlist

All Players

250 Outperform
24 Underperform
 

All-Star Players

62 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:PACB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Breq (83.08)
Submitted July 19, 2016

The rational is the same as for Illumina. Genome sequencing will take on greater and greater importance in the future.

TSIF (99.98)
Submitted October 05, 2015

Releasing a lower cost option should ultimately be good for the bottom line...at least in this case.Sometimes too many models confuses customers and erodes the higher margin upper end of the offering, but in this case, the high end was so high,… More

NASDAQ:PACB VS S&P 500 (SPY)

Fools bullish on NASDAQ:PACB are also bullish on:

Fools bearish on NASDAQ:PACB are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about PACB.

Recs

0
Member Avatar TMFRetireFoolish (26.93) Submitted: 7/8/2021 1:22:52 AM : Outperform Start Price: $33.21 NASDAQ:PACB Score: -11.21

Potential to take leadership role with long read sequencing

Recs

0
Member Avatar 1russianguy (95.33) Submitted: 2/23/2021 1:01:53 PM : Outperform Start Price: $39.35 NASDAQ:PACB Score: -35.88

Three Stocks With 1,000% ROI Potential, as of Feb. 21'. https://www.youtube.com/watch?v=URCkYR_0Ws8

Recs

0
Member Avatar CMFWord (< 20) Submitted: 1/13/2021 10:02:46 PM : Outperform Start Price: $35.34 NASDAQ:PACB Score: -29.70

Long-read sequencing technology is better at identifying structural variants in genomes than short-read sequencing. PacBio's has a lot of growth to realize just from a marketing and sales perspective. The CEO is pushing to get PacBio's systems out to more labs as well as aggressively lower prices. PacBio will overtake Illumina as the dominate sequencing machine provider.

Leaderboard

Find the members with the highest scoring picks in PACB.

Score Leader

IdahoAve

IdahoAve (83.73) Score: +1,570.31

The Score Leader is the player with the highest score across all their picks in PACB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
IdahoAve 83.73 11/28/2012 Outperform 5Y $1.61 +1,785.09% +214.78% +1,570.31 0 Comment
codyjr002 78.14 8/22/2012 Outperform 5Y $1.81 +1,576.80% +211.62% +1,365.18 0 Comment
AFMS 45.42 8/31/2012 Outperform 5Y $1.92 +1,482.38% +210.96% +1,271.42 0 Comment
snscblue1 78.81 9/13/2012 Outperform 5Y $2.00 +1,417.50% +199.97% +1,217.53 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. franniemarie 74.42 7/25/2012 6/19/2018 Outperform 5Y $1.98 +1,432.83% +228.90% +1,203.93 0 Comment
mattyabe < 20 6/25/2012 Outperform 5Y $2.00 +1,417.50% +233.16% +1,184.34 1 Comment
fiveforthemoney 97.06 7/25/2012 Outperform NS $2.03 +1,395.07% +227.56% +1,167.51 0 Comment
TexasChris 71.26 3/18/2013 Outperform 5Y $2.22 +1,267.12% +185.05% +1,082.07 0 Comment
AndreyGR 20.29 5/22/2012 Outperform 5Y $2.24 +1,254.91% +231.45% +1,023.46 0 Comment
vivsiv < 20 4/15/2013 Outperform 3Y $2.34 +1,197.01% +178.44% +1,018.57 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PACB.